Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245982 | 0.87 | GHSR (0.48) | GHSRACLYSMN1; SMN2LMNAMAPT | |
| SCHEMBL2989979 | 0.86 | GHSR (0.46) | GHSRACLYSMN1; SMN2LMNAMAPT | |
| SCHEMBL2985933 | 0.85 | ACLY (0.47) | ACLYLMNAMAPTMEN1HTT | |
| SCHEMBL2992280 | 0.84 | ACLY (0.48) | PTGDRPTGDR2ACLYSMN1; SMN2LMNA | |
| SCHEMBL2984159 | 0.84 | GHSR (0.53) | GHSRPTGDRPTGDR2ACLYSMN1; SMN2 | |
| SCHEMBL2985941 | 0.84 | GHSR (0.53) | GHSRPTGDRPTGDR2ACLYSMN1; SMN2 | |
| SCHEMBL2988756 | 0.84 | IDH1 (0.44) | GHSRPTGDRPTGDR2ACLYSMN1; SMN2 | |
| SCHEMBL2984396 | 0.83 | MAPT (0.53) | ACLYSMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL2995707 | 0.76 | ALDH1A1 (0.46) | ACLYSMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL2990832 | 0.74 | ALDH1A1 (0.51) | SMN1; SMN2LMNAMAPTMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | BLANEY EMMA LOUISE | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179168-A1 | ARYL AND HETEROARYL SULPHONAMIDES AS GROWTH HORMONE SECRETAGOGUE RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | GHSR 1/4885PTGDR 184/4885PTGDR2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.